[Preliminary evaluation of the effectiveness of holoxan in the treatment of malignant soft tissue and bone neoplasms].
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D007223:Infant; D008297:Male; D008875:Middle Aged; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy*; D012512:Sarcoma, Ewing / Q000188:drug therapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D007069:Ifosfamide
Wstepna ocena skuteczności holoxanu w leczeniu nowotworów złośliwych tkanek miekkich i kości.